Stockreport

Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

IMMUNE PHARMACEUTICALS INC NE  (IMNP) 
US:NASDAQ Investor Relations: immunepharma.com/investor-relations
PDF - Results from all subjects confirm excellent safety and tolerability and a large benefit across a variety of efficacy measures despite aggressive prednisone tapering - [Read more]